Kiora Pharmaceuticals
KPRX
18 hedge funds and large institutions have $655K invested in Kiora Pharmaceuticals in 2026 Q1 according to their latest regulatory filings, with 7 funds opening new positions, 4 increasing their positions, 1 reducing their positions, and 7 closing their positions.
300% more repeat investments, than reductions
Existing positions increased: 4 | Existing positions reduced: 1
0% more first-time investments, than exits
New positions opened: 7 | Existing positions closed: 7
5% less funds holding
Funds holding: 19 → 18 (-1)
10.64% less ownership
Funds ownership: 19.22% → 8.59% (-11%)
53% less capital invested
Capital invested by funds: $1.39M → $655K (-$738K)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
+$57.3K |
| 2 |
Geode Capital Management
Boston,
Massachusetts
|
+$54.5K |
| 3 |
TSS
Two Sigma Securities
New York
|
+$25.4K |
| 4 |
RC
Rangeley Capital
New Canaan,
Connecticut
|
+$21.1K |
| 5 |
XT
XTX Topco
George Town,
Cayman Islands
|
+$5.8K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SCM
Stonepine Capital Management
Bend,
Oregon
|
-$258K |
| 2 |
DS
DRW Securities
Chicago,
Illinois
|
-$217K |
| 3 |
NCM
Nantahala Capital Management
New Canaan,
Connecticut
|
-$209K |
| 4 |
Alyeska Investment Group
Chicago,
Illinois
|
-$152K |
| 5 |
Renaissance Technologies
New York
|
-$41.8K |
KPRX Hedge Fund Activity: Q1 2026 in Review
18 of the 8,191 institutional investors tracked by Wall St. Rank reported a position in Kiora Pharmaceuticals (KPRX) for Q1 2026, worth a combined $655K — down 53% from $1.39M a quarter earlier.
Fund positioning in KPRX was balanced in Q1 2026: 7 funds opened new positions, 7 closed out, 4 added to existing stakes and 1 trimmed.
The largest buyer was Citadel Advisors, adding an estimated $57.3K. The largest seller was Stonepine Capital Management, exiting entirely with an estimated $258K sold.
- 18 institutional investors held Kiora Pharmaceuticals (KPRX) as of Q1 2026, down from 19 in Q4 2025.
- Funds reported $655K of Kiora Pharmaceuticals stock for Q1 2026, down 53% quarter-over-quarter.
- 7 funds opened new Kiora Pharmaceuticals positions in Q1 2026 and 7 closed out, a net change of 0 holders.
- The largest Kiora Pharmaceuticals buyer in Q1 2026 was Citadel Advisors, an estimated $57.3K added.
- The largest Kiora Pharmaceuticals seller in Q1 2026 was Stonepine Capital Management, an estimated $258K sold.
Based on aggregated 13F filings for Q1 2026.